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Abstract
Background—The role of HSV-2 in the HIV epidemic, and the potential impact of HSV-2
suppressive therapy, have been previously explored only within the context of sub-Saharan Africa.
In this analysis, modelling is used to estimate: (1) the contribution of herpes simplex virus type-2
(HSV-2) to HIV transmission from clients to female sex workers (FSWs) in a Southern Indian
setting; and (2) the maximum potential impact of ‘perfect’ HSV-2 suppressive therapy on HIV
incidence.
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Methods—A dynamic HSV-2/HIV model was developed, parameterised and fitted to Mysore
data. The model estimated the attributable fractions (AFs) of HIV infections due to HSV-2.
Multivariate sensitivity analyses and regression analyses were conducted.
Results—The model suggests that 36% (95% CI: 22-62%) of FSW HIV infections were due to
HSV-2, mostly through HSV-2 asymptomatic shedding. Even if HSV-2 suppressive therapy could
eliminate the effect of HSV-2 on HIV infectivity among all coinfected clients, only 15% (95% CI:
3-41%) of HIV infections among FSWs would have been averted. 36% (95% CI: 18-61%) of HIV
infections among HSV-2-infected FSWs could have been averted if suppressive therapy reduced
their risk of HIV acquisition to that of the HSV-2-uninfected FSWs.
Conclusions—HSV-2 contributes substantially to HIV in this Southern Indian context.
However, even in the best case scenario, HSV-2 suppressive therapy is unlikely to reduce HIV
transmission or acquisition by more than 50% (as aimed for in recent trials), because of the limited
strength of the interaction effect between HSV-2 and HIV.
Keywords
HIV; Herpes simplex virus type-2; mathematical modelling; India; female sex work
INTRODUCTION
Herpes simplex virus type-2 (HSV-2) is highly prevalent in regions with high HIV
prevalence and among groups at high risk of HIV.1-2 These associations are partly due to
both infections being sexually transmitted, but several lines of biological evidence support
bidirectional synergistic interactions between the two viruses.3-5 In HIV-uninfected
individuals, HSV-2 infection increases susceptibility to HIV through clinical and subclinical
recurrences which disrupt the genital epithelium and increase the density of HIV target cells
in the genital submucosa.5-7 In accord with this evidence, a systematic meta-analysis of
longitudinal studies of the effect of HSV-2 on HIV acquisition showed that, after adjusting
for confounding by age and at least one measure of sexual behaviour, 38-60% of new HIV
infections may be attributable to prevalent HSV-2 infection in women and 8-49% in men, in
the general populations reviewed.8
In HIV-infected individuals, co-infection with HSV-2 may increase HIV infectivity by
upregulating the replication of HIV through different interactions, potentially resulting in
increased rates of HIV transmission from these coinfected individuals.5 In fact, several
cross-sectional studies have observed increased HIV genital shedding and plasma viral loads
in the presence of HSV genital shedding or clinical recurrences.9-12
However, two recent randomised controlled trials evaluating the impact of HSV-2
suppressive therapy (HSVST) on HIV acquisition have shown that acyclovir 400mg twice
daily had no significant effect on HIV incidence.13-14 These disappointing results may be
related to the lack of effectiveness of the intervention, or the possibility that, although the
treatment reduced the HSV-2 virus, it did not cause a reduction in the density of cells which
enhance susceptibility to HIV in HSV-2 infected individuals.713-16 In contrast, results of
randomised controlled trials conducted among dually infected individuals have suggested
that HSV-2 enhances HIV infectivity through demonstrating that HSVST reduces HIV
shedding,17-22 although perhaps not sufficiently to actually reduce HIV transmission from
coinfected individuals23.
Lastly, HSV-2 may also accelerate HIV disease progression by increasing HIV plasma viral
load,24 and HIV could potentially increase HSV-2 infectivity through increased genital
shedding of HSV-2 among coinfected individuals.1025 The latest trial results support this
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hypothesis since HSVST used by those coinfected significantly reduced HIV disease
progression.26
Only four models (albeit applied to several different research questions) have incorporated
both HSV-2 and HIV, and their interactions.27-34 We build on these African and US
focussed analyses, and our previous work35, by using a model to explore the contribution of
HSV-2 to HIV transmission for a female sex worker (FSW) population in Southern India,
where the HIV epidemic is concentrated among high-risk groups. The relative importance of
symptomatic versus asymptomatic HSV-2 genital shedding is explored. The implications of
the findings for the maximum potential impact of HSVST are discussed.
METHODS
Dynamic deterministic models of HSV-2 and HIV were coupled to simulate the
transmission of HIV and HSV-2 among FSWs and their clients. The HSV-2 model is
described elsewhere,35 and includes separate compartments for initial infection (which may
be symptomatic or asymptomatic), the long ‘latent’ phase with infectious asymptomatic
shedding, and periodic short recurrences of infectious symptoms. The HIV model
incorporates the initial short phase of high viral load, followed by the long asymptomatic
phase in which viral load is low. This coupled model was programmed in C and solved
numerically. Further details are supplied in the supplemental online appendix.
The FSWs were modelled as a cohort, with the HSV-2, HIV and coinfection prevalences
being modelled dynamically over the duration of sex work, whereas the client prevalences
were assumed to remain constant over the short timeframe of five years considered. Clients
were assumed to randomly contact FSWs regardless of the duration for which each had sold/
bought sex.
Enhanced transmission of HIV or HSV-2 in the presence of the other infection was
modelled through the use of ‘direct cofactors’ that directly increase the probability of
transmission during each (penile-vaginal) sex act. Additionally, among coinfected
individuals, the symptomatic recurrence rate, proportion shedding asymptomatically, and
rate of progression to AIDS were all assumed to be increased compared with those singly
infected. The effect of other STIs facilitating HIV transmission was included as a constant
cofactor.
Steps in analysis
Parameterisation—The parameter definitions and values used are shown in Table S1 in
the supplemental online appendix, along with further details about the parameterisation
process.
The model was parameterised and fitted using detailed behavioural and epidemiological data
from FSWs in Mysore, Karnataka, and data on clients from Mysore when available, or
elsewhere in Karnataka or other Indian states otherwise.36-37 Data came mostly from two
unpublished surveys undertaken amongst FSWs (2004) and the general population (2005-6)
in Mysore by the Karnataka Health Promotion Trust (KHPT), collected within the
monitoring and evaluation of Avahan, the Bill and Melinda Gates Foundation funded India
AIDS Initiative. The study was approved by the Ethics Review Boards of St Johns Medical
College, Bangalore, India, Centre hospitalier affilié universitaire de Québec, Canada, and
the University of Manitoba, Canada. The cohort model was fitted to HIV, HSV-2 and
coinfection prevalences among FSWs by duration of sex work.
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Uncertainty analysis and model fitting—First the model input parameter ranges were
developed, distributions defined and correlations set (Table S1 in the online appendix). Latin
Hypercube Sampling (LHS) was then used to randomly sample 10,000 parameter sets from
these uncertainty ranges. Those simulations that were rejected in our previous analysis,35 are
discarded here also, along with those predicting too low a prevalence at the start of sex
work, leaving 7,536 simulations.
Any simulation that lay within the 95% confidence intervals (CIs) of the HSV-2, HIV and
HSV-2/HIV coinfection prevalence data among FSWs, by duration of sex work up to five
years, was accepted as a model fit. ‘Least chi-squared’ error was used to identify the best-fit.
However, in addition to using prevalence data among FSWs, the mean values for the HSV-2
and HIV prevalence among the small number of men reporting visiting FSWs (42) in the
unpublished general population survey from Mysore were also used to identify the best-fit.
Calculating attributable fractions—To investigate the contribution HSV-2 makes to
HIV incidence, the model estimates of annual HIV incidence among FSWs after one to five
years of sex work were compared with and without specific interaction cofactors included,
for each model fit. These incidence values were used to calculate the attributable fraction
(AF) of a specific interaction cofactor for increasing HIV transmission by using the
following formula:
(1)
An average AF was calculated after weighting the AFs at each year of sex work by the
proportion having worked in sex work for each equivalent duration. Confidence bounds
were estimated by calculating the AFs for all the model fits and reporting the range spanned
by 95% of the fits.
The model fits were also used to estimate the maximum potential impact that a hypothetical
‘perfect’ HSVST could have on HIV transmission in this FSW population, where ‘perfect’
refers here to completely removing the effect of HSV-2 on either HIV infectivity or HIV
acquisition.
Sensitivity analysis—Multivariate sensitivity analysis using the best-fit simulation was
used to identify which interaction inputs have the greatest effect on the predictions and to
investigate the robustness of the model predictions to key assumptions. Each interaction
model input was given the same relative uncertainty bounds (±20%), and 10,000 parameter
sets were randomly sampled within these bounds using LHS. For each parameter set, the
model was used to produce estimates of the percentage of incident HIV due to HSV-2. The
relative importance of each non-correlated interaction parameter for the model prediction of
the AFs was assessed using multilinear regression.
RESULTS
Selecting the best-fit and description of fits and correlations
Four hundred and one of the 7,536 model simulations fit within the 95% CIs of the observed
HSV-2, HIV and coinfection prevalence data among FSWs. If, as in other similar
analyses,273438 we had only fitted to HSV-2 and HIV prevalences, 688 model fits would
have been identified, leading to wider CIs on the model predictions and lower predictive
power.
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The model best-fit and the epidemiological data used to fit the model are shown in Figure 1.
The input values used in the best-fit are given in Table S1 in the online appendix. The best-
fit predicted an HSV-2 prevalence of 20% and HIV prevalence of 6% among clients (data
estimates were 19% and 5%, respectively).
Attributable fractions
The AFs of all interaction effects of HSV-2 for HIV transmission among FSW are shown in
Table 1, averaged over the first five years of sex work.
Table 1 suggests that 35.5% (95% CI: 22.2-62.5%) of HIV infections among FSWs in
Mysore are due to HSV-2, with the frequent infectious shedding of HSV-2 in the absence of
symptoms contributing much more to HIV incidence than the less frequent recurrences of
infectious symptoms (AF: 32.4% versus 3.0%).
If HSVST reduces the HIV infectivity of all coinfected clients to the same level as singly
HIV-infected clients, then the model projects that 14.6% (95% CI: 3.3-41.2%) of HIV
infections among FSWs would have been averted.
If an average cofactor is calculated that quantifies the overall effect of HSV-2 on HIV
infectivity among coinfected individuals (see supplemental online appendix for details and
figures), then Figure S2a suggests the impact projections are highly correlated to this
average cofactor (linear regression R2=0.880). Indeed, if HSV-2 increases HIV infectivity 3-
fold (up from 1.9-fold in the best-fit) then the linear regression implies that the maximum
impact of ‘perfect’ HSVST for the coinfected clients would be a 34% decrease in HIV
incidence in the FSWs. However, if this cofactor is between 1.25 and 1.43, coinciding with
the shedding data from the trials17-2022-23, and what their translated effect39 means for the
average cofactor, then the regression suggests 7-10% of HIV infections could have been
averted. This projection is in close agreement with the Partners in Prevention trial results of
an 8% reduction in HIV incidence.23
If instead it is assumed that HSVST used by all FSWs singly infected with HSV-2 reduces
their risk of acquiring HIV to that of the HSV-2-uninfected FSWs, the model projects that
36.0% (95% CI: 17.6-60.8%) of HIV infections among HSV-2-infected FSW could have
been averted.
Again, if an average multiplicative cofactor for the effect of HSV-2 on increasing
susceptibility to HIV among individuals singly-infected with HSV-2, is calculated in a
similar way to that described above, then Figure S2b shows the impact projections are
highly correlated to this average cofactor (linear regression R2=0.774). If HSV-2 increases a
FSW’s susceptibility to HIV 5-fold (up from 3.6-fold in the best-fit) then the linear
regression implies that the maximum impact of ‘perfect’ suppressive treatment for the
HSV-2-infected FSWs would be a 55% decrease in HIV incidence among these FSWs. A
lower average cofactor of 2, results in a lower impact estimate of 24%.
Sensitivity analysis
Table 2 shows that the AFs for HIV incidence change by at most 8% in relative terms for a
20% relative change in the interaction input parameters. The AFs are most sensitive to
changes in the direct cofactors, i.e. those that increase the probability of HIV transmission
per sex act in the presence of HSV-2. Other regression coefficients are very small. Table 2
presents the results when the largest cofactors from each correlated pair are entered into the
multilinear regression.
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DISCUSSION
The limitations of the HSV-2 model have been discussed previously,35 mainly that the
model does not allow for sexual behaviour differences during symptomatic versus
asymptomatic shedding.
Since the focus of this study is on the biological interactions between HIV and HSV-2,
sexual behaviour among FSWs is assumed to be homogeneous (and similarly for clients),
and HSV-2 is the only STI that is modelled dynamically. Non-commercial partnerships of
FSWs and clients, or transmission to the general population are ignored, as is the population
of men who have sex with men. Using the model as a cohort model, due to lack of data on
clients, limited the use of the interaction parameters, potentially leading to underestimates in
the attributable fractions.
The model suggests that approximately 36% of HIV infections among FSWs in Mysore are
due to HSV-2. Similarly, another modelling analysis, by Abu-Raddad et al. (2008),
predicted that 35% of HIV infections in Kisumu, Kenya, were attributable to HSV-2.27
Freeman et al. (2007), also used African data in a modelling analysis which found that the
population attributable fraction of HIV due to HSV-2 increases with the maturity of the
epidemic.40
Our model findings emphasise the greater contribution to the HIV epidemic of HSV-2
shedding in the absence of symptoms, than in the presence of symptoms. This is biologically
plausible since, although symptomatic recurrences may be more important per shedding
episode,41 asymptomatic shedding is much more frequent42.
Our analysis suggests that HSVST, used by either FSWs singly-infected with HSV-2 or
clients coinfected with HIV and HSV-2, may reduce HIV incidence among FSWs, but not to
any great extent (by 36% or 15%, respectively). These findings are in close agreement with
White et al. (2008) for a concentrated African epidemic34 and Baggaley et al. (2009) for two
generalised HIV epidemics in sub-Saharan Africa28.
For the main analysis, the values used for the cofactor effect of HSV-2 on susceptibility to
HIV were calculated from reviews and pre-HSVST trial data (e.g. see references 7, 42 and
47 in the online appendix).4 These cofactor values remain valid, despite the lack of
significant impact observed in the HSVST trial of HIV acquisition13-14, since the trial results
do not negate the good biological plausibility and observational data that HSV-2 increases
HIV susceptibility.3-6843-44 The disappointing results from the HIV acquisition trials
compared to the successful HIV shedding trials could be due to many reasons, including
factors relating to the drug choice, dosage strategy and adherence levels13-14, different
effects of the drug in coinfected individuals versus those singly infected with HSV-215-16,
and/or the possible persistence of activated CD8+ T cells which enhance susceptibility to
HIV in HSV-2 infected individuals but are not shut down by HSVST7.
Observing an impact of HSVST in a trial setting may also be difficult because of limited
statistical power. The Partners in Prevention trial was powered to detect a 50% decrease in
HIV incidence,23 yet our modelling suggests that this would have required HSV-2 to
increase the per sex act HIV infectivity, among those coinfected, at least 4-fold. The HIV
acquisition trials were powered at a similar level and our results suggest that an effect of
HSVST would only have been observed if HSV-2 increased HIV susceptibility more than
4.5-fold. For these reasons, it is plausible that the trials observed no impact of HSVST on
HIV incidence simply because the interaction between these viruses is not large enough to
enable a significant impact to be observed for the statistical power set in the trials. The
model strongly supports this premise for the impact of HSVST on HIV transmission (more
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so than acquisition), since even the upper bound on the model-predicted decrease in HIV
incidence is 41% in this case, which is below the 50% that the trials were powered for. The
broader scientific literature suggests that the values of these cofactors are likely to be lower
than what the model suggests is required to observe a statistically significant impact in these
trials (e.g. see references 7, 28, 42, 47, 58-59, 61-65 in the online appendix).45 The Partners
in Prevention trial results also support these model findings since the upper bound on the
impact estimate was 40%,23 implying that there may have been a small impact of acyclovir
which could not achieve the statistical significance required in the trial. Any imperfections
in the effect of HSVST or adherence issues in a trial would require even higher cofactors in
order to observe a statistical significant result.
Given this, the modelling analyses suggest that, although HSV-2 may play an important role
in both concentrated and generalised HIV epidemics, this interaction is likely too weak to
warrant the promotion of HSVST specifically for HIV prevention, given the lack of effect
noted in the trials. However, HSVST in an important intervention for those who are infected
with HSV-2, and may offer broader benefits since it has been demonstrated in a trial to delay
progression to AIDS among those coinfected.26 It also remains possible that HSVST could
have a weak effect on reducing HIV acquisition or transmission by less than 50%. Larger
trials may be able to observe a weak effect of HSVST on HIV incidence but the importance
of conducting such a trial would need to be weighed alongside the costs and relevance of
identifying a low impact product.
Conclusions
This is the first model that has been used to explore the importance of HSV-2 to a
concentrated HIV epidemic in an Asian setting. The modelling suggests that HSV-2 plays a
critical role in the transmission and acquisition of HIV in Mysore, and that this may be
mostly due to infectious shedding of HSV-2 in the absence of symptoms.
Given the successful trial of once-daily valacyclovir to reduce the risk of transmission of
genital herpes46, continuous suppressive treatment of HSV-2 could be an effective strategy
among FSWs and their clients in India, for reducing the transmission of HSV-2. Over time,
the HIV epidemic may be curtailed indirectly through the use of HSV-2 suppressive therapy,
since a lower prevalence of HSV-2 could result in fewer HIV infections.
Increasing the potency of current HSV-2 antiviral drugs may help in further reducing HSV-2
incidence. However, the model suggests that even in the best case scenario, in which HSV-2
suppressive therapy completely removes the effect of HSV-2 on either HIV infectivity or
HIV acquisition, this hypothetical ‘perfect’ therapy is unlikely to lead to a 50% reduction in
HIV incidence, because of the limited strength of the interaction effect between HSV-2 and
HIV.
Modelling analyses such as these should be repeated or adapted and used to explore the
potential impact of other HIV/STI prevention interventions, helping to guide trial design for
expected power and sample size calculations, and to retrospectively inform the interpretation
of trial results.
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Refer to Web version on PubMed Central for supplementary material.
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Key Messages
1. This is the first model exploring the role of HSV-2 in a concentrated HIV
epidemic within an Asian setting.
2. The modelling suggests that HSV-2 plays an important role in the transmission
and acquisition of HIV in Mysore, mostly through asymptomatic HSV-2
shedding.
3. Even in the best-case scenario, HSV-2 suppressive therapy is unlikely to reduce
HIV transmission or acquisition by >50%, as aimed for in recent trials.
4. Modelling analyses can help guide trial design for expected power and sample
size calculations, and retrospectively inform the interpretation of trial results.
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Figure 1. A comparison of the model best-fit with HSV-2 and HIV prevalence and coinfection
prevalence data against the duration of sex work
a Comparison with HSV-2 and HIV prevalence data
b Comparison with HIV/HSV-2 coinfection prevalence data
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Table 1
Average attributable fractions due to specific interactions (percentage of annual HIV
incidence among female sex workers (FSWs) due to interactions with HSV-2)
Best-fit attributable fraction
(95% confidence intervals from all fits)
Specific interaction % of HIV incidence among FSW due to
specific interaction with HSV-2
All interactions combined 35.5(22.2-62.5)
Increased susceptibility and infectivity of HIV in the presence of asymptomatic HSV-2 shedding
alone
32.4
(20.4-59.5)
Increased susceptibility and infectivity of HIV in the presence of symptomatic HSV-2 recurrences
alone
3.0
(1.4-4.3)
Increased susceptibility to HIV among HSV-2-infected FSWs 24.6(11.2-46.7)
Increased infectivity of HIV from coinfected clients* 10.4(2.3-32.5)
*
Includes implicitly the static effect on HIV transmission of the increased HSV-2 symptomatic recurrence rate among coinfected clients
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Table 2
Sensitivity analysis on the effect of a 20% change in model interaction inputs on the
model best-fit attributable fraction of HIV due to HSV-2 among female sex workers
(FSWs)
Model input parameters
(values used for best-fit simulation in parentheses, derived from
Table S1 in the supplemental online appendix)
Relative % change in attributable fraction of HIV incidence
among FSW due to HSV-2 from best-fit value of 35.54%
(absolute value)**
−20% relative change in
parameter
+20% relative change in
parameter
Cofactor for increased transmission of HIV to person symptomatically
shedding HSV-2 (4.5)
−8.10%
(32.66%)
+8.10%
(38.42%)
Cofactor for increased transmission of HIV from coinfected partner
symptomatically shedding HSV-2 (2.7)
−3.70%
(34.22%)
+3.70%
(36.85%)
Cofactor for increased transmission of HSV-2 from coinfected partner
with high HIV viraemia (0.76)
−1.15%
(35.13%)
+1.15%
(35.95%)
Cofactor for increased symptomatic HSV-2 shedding rate in those with
HIV (1.4)
−0.66%
(35.30%)
+0.66%
(35.77%)
Cofactor for increased asymptomatic HSV-2 shedding in those with
HIV (2.4)
−0.24%
(35.45%)
+0.24%
(35.62%)
Cofactor for increased transmission of HSV-2 to a person with high
HIV viraemia (1.7)
+0.14%
(35.59%)
−0.14%
(35.49%)
**
R2 value over 0.98 in the multilinear regression
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